Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?

Bioorganic Chemistry 2026

View at publisher

Authors: Yalan Wang, Wen-Zhe Nie, Fengzhi Lu, Jin-Ying Liu, Ji-Hang He, Ya-Mei Li, Xiao-Ting Li, Qing-Kun Shen

DOI: 10.1016/j.bioorg.2026.109546

Cited by: 3

References: 99

Fields of Study & Subjects

PARP inhibition in cancer therapy Cancer-related Molecular Pathways Advanced Breast Cancer Therapies

References 99